Literature DB >> 34160742

The value of lymphadenectomy in surgical resection of perihilar cholangiocarcinoma: a systematic review and meta-analysis.

Lei Liang1,2, Chao Li3, Ming-Da Wang3, Hao Xing3, Yong-Kang Diao3, Hang-Dong Jia3, Wan Yee Lau3,4, Timothy M Pawlik5, Cheng-Wu Zhang1,2, Feng Shen3, Dong-Sheng Huang6,7, Tian Yang8,9,10.   

Abstract

Surgical resection is the only potentially curative treatment for patients with resectable perihilar cholangiocarcinoma (PHC). There is still no consensus on the value of lymphadenectomy despite evidence indicating lymph node (LN) status is an important prognostic indicator for postoperative long-term survival. We sought to perform a meta-analysis to summarize the current evidence on the value of lymphadenectomy among patients undergoing surgery for PHC. The PubMed (OvidSP), Embase and Cochrane Library were systematically searched for studies published before July 2020 that reported on lymphadenectomy at the time of surgery for PHC after curative surgery. 7748 patients from 28 studies were included in the meta-analysis. No survival benefit was identified with increased number of LN resected (all P > 0.05). Meanwhile, overall LN status was an important prognostic factor. Patients with lymph node metastasis had a pooled estimate hazard ratio of death that was over two-fold higher than patients without lymph node metastasis (HR 2.07, 95% CI 1.65-2.59, P < 0.001). The examination of 5 LNs on histology was associated with better staging of lymph node status and stratification of patients into positive or negative LN groups. While the extent of LN dissection was not associated with a survival benefit, examination of more than 5 LNs better staged patients into positive or negative LN groups with a lower risk of nodal understaging.
© 2021. Japan Society of Clinical Oncology.

Entities:  

Keywords:  Lymphadenectomy; Meta-analysis; Perihilar cholangiocarcinoma; Systematic review

Year:  2021        PMID: 34160742     DOI: 10.1007/s10147-021-01967-z

Source DB:  PubMed          Journal:  Int J Clin Oncol        ISSN: 1341-9625            Impact factor:   3.402


  41 in total

Review 1.  Intrahepatic cholangiocarcinoma: management options and emerging therapies.

Authors:  Rebecca M Dodson; Matthew J Weiss; David Cosgrove; Joseph M Herman; Ihab Kamel; Robert Anders; Jean-Francois H Geschwind; Timothy M Pawlik
Journal:  J Am Coll Surg       Date:  2013-07-24       Impact factor: 6.113

Review 2.  Cholangiocarcinoma: from molecular biology to treatment.

Authors:  Ana F Brito; Ana M Abrantes; João C Encarnação; José G Tralhão; Maria F Botelho
Journal:  Med Oncol       Date:  2015-10-01       Impact factor: 3.064

3.  Lymph node metastasis from hilar cholangiocarcinoma: audit of 110 patients who underwent regional and paraaortic node dissection.

Authors:  Y Kitagawa; M Nagino; J Kamiya; K Uesaka; T Sano; H Yamamoto; N Hayakawa; Y Nimura
Journal:  Ann Surg       Date:  2001-03       Impact factor: 12.969

Review 4.  Improved surgical results for hilar cholangiocarcinoma with procedures including major hepatic resection.

Authors:  T Kosuge; J Yamamoto; K Shimada; S Yamasaki; M Makuuchi
Journal:  Ann Surg       Date:  1999-11       Impact factor: 12.969

5.  Prognostic factors after surgical resection for intrahepatic, hilar, and distal cholangiocarcinoma.

Authors:  Yoshiaki Murakami; Kenichiro Uemura; Takeshi Sudo; Yasushi Hashimoto; Akira Nakashima; Naru Kondo; Ryutaro Sakabe; Hiroki Ohge; Taijiro Sueda
Journal:  Ann Surg Oncol       Date:  2010-10-14       Impact factor: 5.344

Review 6.  Cholangiocarcinoma.

Authors:  Nataliya Razumilava; Gregory J Gores
Journal:  Lancet       Date:  2014-02-26       Impact factor: 79.321

7.  The Blumgart preoperative staging system for hilar cholangiocarcinoma: analysis of resectability and outcomes in 380 patients.

Authors:  Kenichi Matsuo; Flavio G Rocha; Kaori Ito; Michael I D'Angelica; Peter J Allen; Yuman Fong; Ronald P Dematteo; Mithat Gonen; Itaru Endo; William R Jarnagin
Journal:  J Am Coll Surg       Date:  2012-06-28       Impact factor: 6.113

8.  Cholangiocarcinoma: thirty-one-year experience with 564 patients at a single institution.

Authors:  Michelle L DeOliveira; Steven C Cunningham; John L Cameron; Farin Kamangar; Jordan M Winter; Keith D Lillemoe; Michael A Choti; Charles J Yeo; Richard D Schulick
Journal:  Ann Surg       Date:  2007-05       Impact factor: 12.969

9.  Prognosis of perihilar cholangiocarcinoma: hilar bile duct cancer versus intrahepatic cholangiocarcinoma involving the hepatic hilus.

Authors:  Tsuyoshi Sano; Kazuaki Shimada; Yoshihiro Sakamoto; Hidenori Ojima; Minoru Esaki; Tomoo Kosuge
Journal:  Ann Surg Oncol       Date:  2007-12-05       Impact factor: 5.344

10.  Surgical treatment of cholangiocellular carcinoma.

Authors:  R Pichlmayr; P Lamesch; A Weimann; G Tusch; B Ringe
Journal:  World J Surg       Date:  1995 Jan-Feb       Impact factor: 3.352

View more
  2 in total

1.  Impact of Positive Lymph Nodes and Resection Margin Status on the Overall Survival of Patients with Resected Perihilar Cholangiocarcinoma: The ENSCCA Registry.

Authors:  Lynn E Nooijen; Jesus M Banales; Marieke T de Boer; Chiara Braconi; Trine Folseraas; Alejandro Forner; Waclaw Holowko; Frederik J H Hoogwater; Heinz-Josef Klümpen; Bas Groot Koerkamp; Angela Lamarca; Adelaida La Casta; Flora López-López; Laura Izquierdo-Sánchez; Alexander Scheiter; Kirsten Utpatel; Rutger-Jan Swijnenburg; Geert Kazemier; Joris I Erdmann
Journal:  Cancers (Basel)       Date:  2022-05-12       Impact factor: 6.575

2.  Comparison of Efficacy and Safety Between Laparoscopic and Open Radical Resection for Hilar Cholangiocarcinoma-A Propensity Score-Matching Analysis.

Authors:  Yong-Gang He; Wen Huang; Qian Ren; Jing Li; Feng-Xia Yang; Chang-Lin Deng; Li-Qi Li; Xue-Hui Peng; Yi-Chen Tang; Lu Zheng; Xiao-Bing Huang; Yu-Ming Li
Journal:  Front Oncol       Date:  2022-09-26       Impact factor: 5.738

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.